Study of TPI 287 in Patients With Advanced Malignancies

Inclusion Criteria:

* Histological or cytological evidence of malignancy
* Patients must have either:

  * advanced solid tumors that have recurred or progressed following standard therapy, or
  * Hodgkin's or non-Hodgkin's lymphoma that has recurred or progressed following standard therapy, have not had a previous bone marrow transplant, and are not eligible for a bone marrow transplant.
* Failed at least one previous therapeutic regimen and either no longer are candidates for standard therapy, have no standard therapy available, or choose not to pursue standard therapy.
* Ambulatory with ECOG 0 or 1, and a life expectancy of \>3 months.
* Judged by the investigator to have the initiative and means to be compliant with the protocol and be within geographical proximity to make the required study visits.
* Have ability to read, understand and provide written informed consent for the initiation of any study related procedures or have a legal representative to perform this function.
* If female, must have a negative pregnancy test within 21 days of start of treatment.
* Agree to the use of an effective method of contraception during the study and for 90 days following the last dose of medication.
* Patients with prior radiation therapy for brain metastasis or primary brain tumors are acceptable.

Exclusion Criteria:

* Prior radiation therapy or chemotherapy within 4 weeks (6 weeks for prior nitrosoureas or mitomycin)
* Another active medical condition(s) or organ disease(s) that may either compromise patient safety or interfere with the safety and/or outcome evaluation of the study drug. While this exclusion is not limited to the following abnormalities, if any of the following laboratory abnormalities are present, the patient should be excluded:

  * WBC \< 3000/uL;
  * Absolute neutrophil count \< 1500/uL;
  * Platelets \< 100,000/uL;
  * Total bilirubin \> 1.5 x upper limit of normal;
  * ALT or AST \> 3 x upper limit of normal if no liver metastases or \>5 upper limit of normal in the presence of liver metastases;
  * Serum creatinine \> 1.5 x upper limit of normal;
  * INR \>2.0.
* Patient has clinically significant cardiac co-morbidities or pulmonary impairment
* Patient or physician plans concomitant chemotherapy, radiation therapy, hormonal and/or biological treatment for cancer including immunotherapy while on study. Of note, therapy with LHRH for prostate cancer is acceptable.
* Patient has been treated with any investigational drug, investigational biologic, or investigational therapeutic device within 30 days of initiating study treatment.
* Tumor appears to involve a major artery or vein.
* Prior or concurrent significant CNS disease including stroke, except for primary or secondary malignancies.
* Less than 4 weeks since prior major surgery
* Known positive for HIV, Hepatitis B or C
* Concurrent chronic use of aspirin (325 mg/day or more)
* Concurrent or recent (within 1 month) use of thrombolytic agents, or full-dose anticoagulants (except to maintain patency of preexisting, permanent indwelling IV catheters) Of note, therapy with low-molecular weight heparin is acceptable as long as the INR\<2.0.
* Uncontrolled hypertension
* Grade II-IV peripheral vascular disease within the past year
* Prior allergic reactions to compounds of similar chemical or biologic composition to TPI 287, paclitaxel or taxotere, Cremophor-EL-P, or other study agents
* Significant traumatic injury within the past 4 weeks
* Ongoing or active infection requiring parenteral antibiotics or with a fever \>38.1°C within 3 days of the first scheduled day of dosing
* Other concurrent uncontrolled illness which may interfere with the ability of the patient to participate in the trial
* Patients who are inpatients
* Grade II-IV peripheral neuropathy